

Castrate-Resistant Prostate Cancer Market Report and Forecast 2024-2032

Market Report | 2023-09-12 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Castrate Resistant Prostate Cancer Market Report and Forecast 2024-2032

Castrate Resistant Prostate Cancer Market Outlook

The castrate resistant prostate cancer market was valued at USD 11.2 billion in 2023, driven by increasing collaboration among pharmaceutical companies. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 23.5 billion by 2032.

Castrate Resistant Prostate Cancer: Introduction

Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to medical or surgical interventions that lower testosterone levels in the body, such as surgical castration (removal of the testicles) or androgen deprivation therapy (ADT). Testosterone is a male hormone that can stimulate the growth of prostate cancer cells. When prostate cancer becomes resistant to these therapies, it can continue to grow and spread even in the absence of testosterone.

Key Trends in the Global Castrate Resistant Prostate Cancer Market

The castrate resistant prostate cancer market has been experiencing significant growth and evolution in recent years. Several key trends are some key trends shaping the market:

- **Emerging Therapies:** New therapeutic options, including novel androgen receptor-targeted therapies, immunotherapies, and radiopharmaceuticals, are continuing to emerge. These treatments aim to provide improved efficacy and fewer side effects for CRPC patients.
- **Biomarker-Driven Treatment:** Personalized medicine approaches are gaining prominence. Biomarker testing helps identify specific genetic mutations or protein markers that guide treatment decisions, ensuring patients receive therapies tailored to their unique molecular profiles.
- **Immunotherapy Advancements:** Immune checkpoint inhibitors and other immunotherapies are being explored for their potential in treating CRPC. These therapies aim to harness the patient's immune system to target cancer cells.
- **Radiopharmaceuticals:** Radiopharmaceuticals such as radium-223 (Xofigo) have been approved for the treatment of CRPC

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

patients with bone metastases. This trend continues to evolve with the development of new agents.

-□Combination Therapies: Researchers and pharmaceutical companies are investigating combination therapies that target multiple pathways involved in CRPC simultaneously. This approach aims to enhance treatment efficacy and delay disease progression.

Castrate Resistant Prostate Cancer Market Segmentations

The market can be categorized into therapy type, therapy drug class, route of administration, distribution channel, and region.

Market Breakup by Therapy Type

- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Others

Market Breakup by Therapy Drug Class

- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Others

Market Breakup by Route of Administration

- Oral
- Parenteral

Market Breakup by Distribution Channel

- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy

Market Breakup by Region -7MM

- United States
- EU-4 and the United Kingdom
- Japan

Castrate Resistant Prostate Cancer Market Overview

The market for Castrate Resistant Prostate Cancer (CRPC) continues to be a significant and evolving aspect of the oncology landscape. CRPC, a stage of prostate cancer that no longer responds to hormone therapy, has seen notable advancements in diagnosis and treatment. Innovative therapies, including next-generation anti-androgens and immunotherapies, have been approved and are offering new hope to patients with CRPC. Additionally, molecular profiling and precision medicine approaches are gaining prominence in tailoring treatments to individual patients, enhancing their efficacy, and reducing side effects. Clinical trials are ongoing, exploring novel therapeutic modalities, combination therapies, and biomarker-driven interventions. The CRPC market remains dynamic, with a focus on improving patient outcomes, enhancing the quality of life, and extending survival for those affected by this challenging form of cancer. Collaboration among pharmaceutical companies, research institutions, and healthcare providers plays a pivotal role in advancing CRPC treatment options.

Key Players in the Castrate Resistant Prostate Cancer Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the castrate resistant prostate cancer market are as follows:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [] Sanofi
- [] Johnson & Johnson Services Inc.
- [] Pfizer Inc.
- [] Astellas Pharma, Inc.
- [] Bayer AG
- [] F. Hoffmann-La Roche Ltd.
- [] Mylan N.V.
- [] Teva Pharmaceutical Industries Ltd.
- [] GlaxoSmithKline plc
- [] Novartis AG
- [] Eli Lilly and Company
- [] Merck & Co., Inc.
- [] Allergan
- [] AstraZeneca
- [] Cipla Inc.
- [] Amneal Pharmaceuticals LLC

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Castrate-Resistant Prostate Cancer Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Castrate-Resistant Prostate Cancer Epidemiology Analysis-7MM
 - 5.1 Epidemiology Overview (2017-2032)
 - 5.2 United States Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
 - 5.3 EU-4 and United Kingdom Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
 - 5.4 Japan Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
- 6 Castrate-Resistant Prostate Cancer Market Overview
 - 6.1 Castrate-Resistant Prostate Cancer Market Historical Value (2017-2023)
 - 6.2 Castrate-Resistant Prostate Cancer Market Forecast Value (2024-2032)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7 Castrate-Resistant Prostate Cancer Market Landscape
 - 7.1Castrate-Resistant Prostate Cancer: Developers Landscape
 - 7.1.1Analysis by Year of Establishment
 - 7.1.2Analysis by Company Size
 - 7.1.3Analysis by Region
 - 7.2Castrate-Resistant Prostate Cancer: Product Landscape
 - 7.2.1Analysis by Therapy Type
 - 7.2.2Analysis by Drug Class
 - 7.2.3Analysis by Route of Administration
- 8Castrate-Resistant Prostate Cancer Challenges and Unmet Needs
 - 8.1Treatment Pathway Challenges
 - 8.2Compliance and Drop-Out Analysis
 - 8.3Awareness and Prevention Gaps
- 9Cost of Treatment
- 10 Castrate-Resistant Prostate Cancer Market Dynamics
 - 10.1Market Drivers and Constraints
 - 10.2SWOT Analysis
 - 10.3Porter's Five Forces Model
 - 10.4Key Demand Indicators
 - 10.5Key Price Indicators
 - 10.6Industry Events, Initiatives, and Trends
 - 10.7Value Chain Analysis
- 11 Castrate-Resistant Prostate Cancer Market Segmentation
 - 11.1 Castrate-Resistant Prostate Cancer Market by Therapy Type
 - 11.1.1Market Overview
 - 11.1.2Hormonal Therapy
 - 11.1.3Immunotherapy
 - 11.1.4Chemotherapy
 - 11.1.5Others
 - 11.2 Castrate-Resistant Prostate Cancer Market by Therapy Drug Class
 - 11.2.1Market Overview
 - 11.2.2Antineoplastic
 - 11.2.3Non-steroidal Antiandrogen
 - 11.2.4Corticosteroids
 - 11.2.5Others
 - 11.3 Castrate-Resistant Prostate Cancer Market by Route of Administration
 - 11.3.1Market Overview
 - 11.3.2Oral
 - 11.3.3Parenteral
 - 11.4 Castrate-Resistant Prostate Cancer Market by Distribution Channel
 - 11.4.1Market Overview
 - 11.4.2Hospital Pharmacy
 - 11.4.3Retail Pharmacy
 - 11.4.4Online Pharmacy
 - 11.5 Castrate-Resistant Prostate Cancer Market by Region -7MM
 - 11.5.1Market Overview
 - 11.5.2United States

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.5.3EU-4 and the United Kingdom
- 11.5.4Japan
- 12United States Castrate-Resistant Prostate Cancer Market
 - 12.1U.S. Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
 - 12.2U.S. Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
 - 12.3Market Size by Therapeutic Class
- 13EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market
 - 13.1EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
 - 13.2EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
 - 13.3Market Size by Therapeutic Class
- 14Japan Castrate-Resistant Prostate Cancer Market
 - 14.1Japan Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
 - 14.2Japan Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
 - 14.3Market Size by Therapeutic Class
- 15Regulatory Framework
 - 15.1Regulatory Overview
 - 15.1.1US FDA
 - 15.1.2EU EMA
 - 15.1.3JAPAN PMDA
- 16Patent Analysis
 - 16.1Analysis by Type of Patent
 - 16.2Analysis by Publication year
 - 16.3Analysis by Issuing Authority
 - 16.4Analysis by Patent Age
 - 16.5Analysis by CPC Analysis
 - 16.6Analysis by Patent Valuation
 - 16.7Analysis by Key Players
- 17Grants Analysis
 - 17.1Analysis by year
 - 17.2Analysis by Amount Awarded
 - 17.3Analysis by Issuing Authority
 - 17.4Analysis by Grant Application
 - 17.5Analysis by Funding Institute
 - 17.6Analysis by NIH Departments
 - 17.7Analysis by Recipient Organization
- 18Clinical Trials Analysis
 - 18.1 Analysis by Trial Registration Year
 - 18.2Analysis by Trial Status
 - 18.3Analysis by Trial Phase
 - 18.4Analysis by Therapeutic Area
 - 18.5Analysis by Geography
- 19Funding and Investment Analysis
 - 19.1Analysis by Funding Instances
 - 19.2Analysis by Type of Funding
 - 19.3Analysis by Funding Amount
 - 19.4Analysis by Leading Players
 - 19.5Analysis by Leading Investors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.6Analysis by Geography
- 20Partnership and Collaborations Analysis
- 20.1Analysis by Partnership Instances
- 20.2Analysis by Type of Partnership
- 20.3Analysis by Leading Players
- 20.4Analysis by Geography
- 21Supplier Landscape
- 21.1Sanofi
 - 21.1.1Financial Analysis
 - 21.1.2Product Portfolio
 - 21.1.3Demographic Reach and Achievements
 - 21.1.4Mergers and Acquisitions
 - 21.1.5Certifications
- 21.2Johnson & Johnson Services Inc.
 - 21.2.1Financial Analysis
 - 21.2.2Product Portfolio
 - 21.2.3Demographic Reach and Achievements
 - 21.2.4Mergers and Acquisitions
 - 21.2.5Certifications
- 21.3Pfizer Inc.
 - 21.3.1Financial Analysis
 - 21.3.2Product Portfolio
 - 21.3.3Demographic Reach and Achievements
 - 21.3.4Mergers and Acquisitions
 - 21.3.5Certifications
- 21.4Astellas Pharma, Inc.
 - 21.4.1Financial Analysis
 - 21.4.2Product Portfolio
 - 21.4.3Demographic Reach and Achievements
 - 21.4.4Mergers and Acquisitions
 - 21.4.5Certifications
- 21.5Bayer AG
 - 21.5.1Financial Analysis
 - 21.5.2Product Portfolio
 - 21.5.3Demographic Reach and Achievements
 - 21.5.4Mergers and Acquisitions
 - 21.5.5Certifications
- 21.6F. Hoffmann-La Roche Ltd.
 - 21.6.1Financial Analysis
 - 21.6.2Product Portfolio
 - 21.6.3Demographic Reach and Achievements
 - 21.6.4Mergers and Acquisitions
 - 21.6.5Certifications
- 21.7Mylan N.V.
 - 21.7.1Financial Analysis
 - 21.7.2Product Portfolio
 - 21.7.3Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.7.4Mergers and Acquisitions
- 21.7.5Certifications
- 21.8Teva Pharmaceutical Industries Ltd.
- 21.8.1Financial Analysis
- 21.8.2Product Portfolio
- 21.8.3Demographic Reach and Achievements
- 21.8.4Mergers and Acquisitions
- 21.8.5Certifications
- 21.9GlaxoSmithKline plc
- 21.9.1Financial Analysis
- 21.9.2Product Portfolio
- 21.9.3Demographic Reach and Achievements
- 21.9.4Mergers and Acquisitions
- 21.9.5Certifications
- 21.10Novartis AG
- 21.10.1Financial Analysis
- 21.10.2Product Portfolio
- 21.10.3Demographic Reach and Achievements
- 21.10.4Mergers and Acquisitions
- 21.10.5Certifications
- 21.11Eli Lilly and Company
- 21.11.1Financial Analysis
- 21.11.2Product Portfolio
- 21.11.3Demographic Reach and Achievements
- 21.11.4Mergers and Acquisitions
- 21.11.5Certifications
- 21.12Merck & Co., Inc.
- 21.12.1Financial Analysis
- 21.12.2Product Portfolio
- 21.12.3Demographic Reach and Achievements
- 21.12.4Mergers and Acquisitions
- 21.12.5Certifications
- 21.13Allergan
- 21.13.1Financial Analysis
- 21.13.2Product Portfolio
- 21.13.3Demographic Reach and Achievements
- 21.13.4Mergers and Acquisitions
- 21.13.5Certifications
- 21.14AstraZeneca
- 21.14.1Financial Analysis
- 21.14.2Product Portfolio
- 21.14.3Demographic Reach and Achievements
- 21.14.4Mergers and Acquisitions
- 21.14.5Certifications
- 21.15Cipla Inc.
- 21.15.1Financial Analysis
- 21.15.2Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.15.3Demographic Reach and Achievements
- 21.15.4Mergers and Acquisitions
- 21.15.5Certifications
- 21.16Amneal Pharmaceuticals LLC
- 21.16.1Financial Analysis
- 21.16.2Product Portfolio
- 21.16.3Demographic Reach and Achievements
- 21.16.4Mergers and Acquisitions
- 21.16.5Certifications
- 22Castrate-Resistant Prostate Cancer - Distribution Model (Additional Insight)
- 22.1Overview
- 22.2Potential Distributors
- 22.3Key Parameters for Distribution Partner Assessment
- 23Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24Company Competitiveness Analysis (Additional Insight)
- 24.1Very Small Companies
- 24.2Small Companies
- 24.3Mid-Sized Companies
- 24.4Large Companies
- 24.5Very Large Companies
- 25Payment Methods (Additional Insight)
- 25.1Government Funded
- 25.2Private Insurance
- 25.3Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Castrate-Resistant Prostate Cancer Market Report and Forecast 2024-2032

Market Report | 2023-09-12 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com